US Pharma MarketingFor wearables, it’s a GLP-1 world
Signos raised $20 million for its approach to using continuous glucose monitors to help people lose weight. And Oura unveiled today its latest, smallest ring. Topic Hubs AI drug discovery: News, analysis and interviews Antibody-drug conjugates: The next wave of targeted cancer drugs Biopharma M&A and dealmaking: Who’s buying and why Biopharma people moves: CEO changes, executive hires, board positions Biotech IPOs: Tracking the market for new public offerings Biotech venture funding: Who’s raising and where the money is going Cell and gene therapy manufacturing: Scaling the next frontier China biotech: Licensing deals and the Biosecure Act CRISPR and gene…
We have two pieces of wearables-related news for you today, and (maybe unsurprisingly) GLP-1s came up in our conversations with both companies.
First, Signos raised $20 million for its approach ...
Source: Endpoints News